T-cell-based breast cancer immunotherapy
T-cell-based breast cancer immunotherapy
复制标题
DOI：
10.1016/j.semcancer.2020.05.019
复制
发表时间：
2021-05-17
影响因子：
14.5
通讯作者：
Losurdo, Agnese
中科院分区：
文献类型：
--
作者：
Pilipow, Karolina;Darwich, Abbass;Losurdo, Agnese
随着免疫检查点抑制剂的出现，癌症免疫治疗见证了新的复兴，免疫检查点抑制剂可以重新激活T细胞，促进内源性抗肿瘤反应。免疫治疗在黑色素瘤、肾癌、肺癌和其他传统上被认为具有免疫原性的癌症领域的出色结果，重新点燃了肿瘤学社区的兴趣，将其扩展到包括乳腺癌(BC)在内的所有癌症。在这篇综述中，我们强调了使用T细胞作为临床实践和治疗方案的标志物的现状。
Cancer immunotherapy has witnessed a new renaissance with the advent of immune checkpoint inhibitors, which reactivate T cells and foster endogenous anti-tumor responses. The excellent results of immunotherapy in the field of melanoma, renal cancer, lung cancer, and other cancer types that have traditionally been known to be immunogenic, rekindled the interest of the oncology community in extending the benefits to all cancers including breast cancer (BC). In this review, we highlight the current state of using T cells as both markers for clinical practice and therapeutic options for BC.